Cancer treatment could identify patients most likely to respond to cancer drugs
Tumours with high mtDNA mutations more likely to respond to Opdivo
Read More
Tag: Memorial Sloan Kettering Cancer Centre
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
